Form 4: Xilio Therapeutics Director Receives Stock Option Grant

Director Akintunde Olatokumbo Bello was granted 5,000 stock options in Xilio Therapeutics, Inc. on June 11, 2026.

Summary

• Director Akintunde Olatokumbo Bello received a grant of 5,000 stock options.
• The options have an exercise price of $7.99 per share.
• The grant date for these options is June 11, 2026.
• The options are set to expire on June 10, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential future dilution of existing shareholders upon the exercise of these options.

Risks

• The value of the options is dependent on the future performance of Xilio Therapeutics' common stock price exceeding the $7.99 exercise price.

Future Outlook

The options vest 100% on the earlier of June 11, 2027, or the date of the Issuer's next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to incentivize board members and align their interests with long-term corporate performance.

Comparison to Industry Standards

• The grant of stock options to directors is a common practice among small-cap biotechnology firms to preserve cash while providing competitive compensation packages.

Stakeholder Impact

• Minor impact on shareholders due to potential future dilution from the issuance of 5,000 shares upon exercise.

Next Steps

• Vesting of the 5,000 options on June 11, 2027, or the next annual meeting of stockholders.

Key Dates

Keywords

Xilio Therapeutics, XLO, Form 4, Insider Trading, Stock Options, Director Compensation